Weekly Research Analysts’ Ratings Changes for RxSight (RXST)

RxSight (NASDAQ: RXST) has recently received a number of price target changes and ratings updates:

  • 11/12/2026 – RxSight was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
  • 11/7/2026 – RxSight was upgraded by Wall Street Zen from “sell” to “hold”.
  • 11/4/2026 – RxSight had its price target lowered by Wells Fargo & Company from $9.00 to $6.00. They now have an “equal weight” rating on the stock.
  • 11/4/2026 – RxSight had its price target lowered by Piper Sandler from $10.00 to $8.00. They now have a “neutral” rating on the stock.
  • 11/4/2026 – RxSight had its price target lowered by Needham & Company LLC from $11.00 to $7.00. They now have a “buy” rating on the stock.
  • 10/25/2026 – RxSight was downgraded by Wall Street Zen from “hold” to “sell”.
  • 10/17/2026 – RxSight was upgraded by Wall Street Zen from “sell” to “hold”.
  • 10/3/2026 – RxSight was downgraded by Wall Street Zen from “hold” to “sell”.
  • 9/22/2026 – RxSight had its price target lowered by Jefferies Financial Group from $6.50 to $5.75. They now have a “hold” rating on the stock.
  • 9/22/2026 – RxSight had its price target lowered by Bank of America from $6.50 to $5.50. They now have an “underperform” rating on the stock.
  • 9/20/2026 – RxSight was upgraded by Wall Street Zen from “sell” to “hold”.

RxSight Stock Up 3.7%

Shares of RxSight stock opened at $5.01 on Thursday. The stock has a market capitalization of $210.07 million, a price-to-earnings ratio of -3.91 and a beta of 1.21. RxSight, Inc. has a twelve month low of $4.11 and a twelve month high of $13.22. The company has a 50-day simple moving average of $4.96 and a two-hundred day simple moving average of $6.09.

RxSight (NASDAQ:RXST – Get Free Report) last announced its earnings results on Tuesday, November 3rd. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.08). RxSight had a negative return on equity of 20.11% and a negative net margin of 43.80%. The business had revenue of $24.59 million for the quarter, compared to analyst estimates of $27.19 million. On average, sell-side analysts anticipate that RxSight, Inc. will post -0.78 earnings per share for the current fiscal year.

Insider Activity at RxSight

In other RxSight news, CFO Mark Wilterding sold 7,765 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $6.96, for a total transaction of $54,044.40. Following the transaction, the chief financial officer owned 25,049 shares in the company, valued at $174,341.04. This trade represents a 23.66% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Ronald M. Md Kurtz sold 5,100 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $6.96, for a total value of $35,496.00. Following the transaction, the insider owned 71,775 shares in the company, valued at approximately $499,554. This trade represents a 6.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 16,947 shares of company stock valued at $117,951. 10.05% of the stock is currently owned by corporate insiders.

RxSight, Inc. is a medical technology company focused on products for cataract surgery and vision correction. Its main offering is the Light Adjustable Lens (LAL), an intraocular lens implanted during cataract surgery that can be adjusted after the procedure to refine a patient’s vision. Adjustments are made with RxSight’s Light Delivery Device, which uses ultraviolet light to change the lens’s optical power. The company also provides related treatment-planning and patient-care products and services for clinicians using the LAL system.

Read More

Receive News & Ratings for RxSight Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight Inc and related companies with MarketBeat.com's FREE daily email newsletter.